Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
about
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue.Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancerCancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.Personalized medicine and cancer.KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patientsPotential of soluble CD26 as a serum marker for colorectal cancer detection.Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastasesBiomarkers, bundled payments, and colorectal cancer care.Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.Pharmacogenetic biomarkers for predicting drug response.DNA synthesis inhibitors for the treatment of gastrointestinal cancer.Genomic characterization of liver metastases from colorectal cancer patients.A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.The role of the pathology department in the preanalytical phase of molecular analyses.Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy.
P2860
Q31043717-2BE9B8E0-1741-4329-9D97-B747B3AF741CQ33750119-8001B860-B3C8-402B-A497-94773373B3D4Q34537690-1330E161-8624-49F1-A820-28B8368098E0Q34608577-17FD33CE-8BCF-48EC-9D92-FF2D8293691FQ35045790-90A5628F-A9B4-44C1-B598-FE27AB8449F7Q35113393-D32475AE-DF86-4CE1-9B4A-859F27D12B6AQ35666492-2471B56E-0D0C-4516-9E89-786B7235299CQ36153320-A6ECA1D8-C547-45DD-A1C7-8F824DE6F486Q36810728-207BA40B-D7A6-46BE-B2F9-5F0E70FC8767Q37182264-D1911310-F168-4C57-95B3-D6F529767D40Q37411227-4A6E882F-3CF0-41F5-B2FC-67E59664871EQ38214388-B3798DA7-CB15-4D9F-8226-FD00BF445281Q38254307-D1ABDAA2-DDA8-448B-A28E-7ACCEEAC23D7Q42317553-FE9CA4B4-311E-408A-A862-1D4B98A68078Q46448007-82DCFFFB-704C-4AA2-9376-7BD33D2CA2ABQ52562703-7769F1F3-E2FD-4687-AD0B-E71F4FF8D2DFQ52968768-B1645FC0-1871-4669-9057-67DAB75B3D52
P2860
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Personalized medicine and onco ...... omarkers in colorectal cancer.
@en
type
label
Personalized medicine and onco ...... omarkers in colorectal cancer.
@en
prefLabel
Personalized medicine and onco ...... omarkers in colorectal cancer.
@en
P2093
P2860
P356
P1476
Personalized medicine and onco ...... omarkers in colorectal cancer.
@en
P2093
Alan P Venook
Kathryn A Phillips
Robin K Kelley
Stephanie L Van Bebber
P2860
P356
10.6004/JNCCN.2011.0004
P577
2011-01-01T00:00:00Z